Leukaemia (chronic myeloid) - imatinib (TA70) (partially updated by TA241 and TA251)
The clinical and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia
This guidance has been partially updated by TA241 Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) and TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
This page was last updated: 31 May 2012
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.